News

Verisk Surprises with Earnings Beat and Revenue Growth

Verisk Surprises with Earnings Beat and Revenue Growth

Verisk Outperforms Earnings Expectations

Verisk (NASDAQ: VRSK) recently announced their third quarter earnings, revealing an earnings per share (EPS) of $1.67. This figure surpassed analyst expectations by $0.07, with the consensus estimate being $1.60. Additionally, the company's revenue for the quarter was reported at $725.3 million, comfortably exceeding the predicted $722.19 million.

Future Guidance and Expectations

Looking ahead, Verisk has provided a robust guidance for the fiscal year 2024. The company anticipates an EPS between $6.30 and $6.60, which is slightly below the analyst consensus of $6.56. For revenue, Verisk projects a range of $2.84 billion to $2.90 billion, again in alignment with the expected consensus of $2.87 billion.

Stock Performance Summary

The company’s stock closed at $263.65, indicating a decline of 1.13% over the past three months. However, over the last twelve months, Verisk's stock price has appreciated significantly, showcasing a gain of 15.96%.

Analyst Revisions Insights

In the 90-day analysis period, Verisk has seen a total of 0 positive EPS revisions alongside 13 negative revisions. This could suggest mixed sentiment among analysts about the company's near-term performance despite its strong earnings report.

Financial Health and Performance Metrics

According to available financial analysis tools, Verisk’s financial health score is rated as "good performance." This positive assessment highlights the company’s stability and growth potential amidst challenging market conditions.

Conclusion

Verisk has demonstrated notable performance in the third quarter, with impressive earnings and revenue figures. The outlook for FY 2024 remains cautiously optimistic, positioning the company for continued success in the market.

Frequently Asked Questions

What was Verisk's EPS for the third quarter?

Verisk reported an EPS of $1.67 for the third quarter, exceeding analyst expectations by $0.07.

How did Verisk's revenue compare to expectations?

The company's revenue for the quarter was $725.3 million, which was above the consensus estimate of $722.19 million.

What is the guidance provided by Verisk for FY 2024?

Verisk’s guidance for FY 2024 is an EPS of $6.30 to $6.60 and revenue between $2.84 billion and $2.90 billion.

What is the current stock performance of Verisk?

As of the last report, Verisk's stock is priced at $263.65, down 1.13% in the last three months but up 15.96% over the last year.

How many EPS revisions has Verisk seen recently?

In the past 90 days, there have been 0 positive EPS revisions and 13 negative revisions for Verisk.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Western Microsurgical Expands Through Strategic Acquisitions

Updated Category News Views 67

Western Microsurgical's Bold Moves Western Microsurgical (WMS) is out here making waves, pulling off some serious strategic plays with the acquisitions of Q Surgical and Proficient Surgical. Now, this ain't some fly-by-night decision—this is about securing territory and leveling up their game in surgical microscopes and operating room supplies. With a footprint that'll...

Continue Reading
U.S.-Saudi Business Leaders Eye Growth Amid Challenges

Updated Category News Views 107

Revitalizing a Strategic Partnership Monday's meeting of the U.S.-Saudi Business Council wasn't just another gathering of suits; it was about re-kindling the investment flame between these two economic giants. Chaired by powerhouses Lubna Olayan and Jane Fraser, this wasn't a mere photo op. It was a call to arms in a landscape riddled with hurdles but bursting with...

Continue Reading
DexCom Faces Scrutiny: Fiduciary Breach Questioned

Updated Category News Views 190

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

Continue Reading
North Fork Mono Casino Opens: A $750 Million Bet

Updated Category News Views 57

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

Continue Reading
DICK'S Sporting Goods Faces Investor Lawsuit Deadline Looms

Updated Category News Views 23

A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....

Continue Reading
Noma Hits Fortune Cyber 60 with AI Security Success

Updated Category News Views 13

Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...

Continue Reading
oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

Updated Category News Views 57

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

Continue Reading
Bank Leumi Q3 Earnings Preview: Key Dates & Insights

Updated Category News Views 61

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Continue Reading
Jiahui's Bold Leap into Global Cell Therapy Market

Updated Category News Views 66

Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...

Continue Reading
CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 19

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading